Researchers Urge EBV Antivirals for MS After 2-Fold T-Cell Signal Emerges
Updated
Updated · New Scientist · Jul 15
Researchers Urge EBV Antivirals for MS After 2-Fold T-Cell Signal Emerges
3 articles · Updated · New Scientist · Jul 15
Summary
A 30-patient MS analysis found most CD4 T-cells targeting Epstein-Barr virus were reacting to proteins made during active viral replication, not its dormant phase.
Those patients had about twice as many of these EBV-targeting T-cells as 30 people without MS, pointing to an abnormal immune response to active infection.
In 60 people with MS, B-cell-depleting treatment cut the EBV-directed T-cell response to near-control levels, while saliva EBV dropped below detection in most patients after therapy.
The findings suggest current MS drugs may work partly by removing EBV-infected B-cells, raising the prospect that direct antivirals could match efficacy with fewer immune-suppressing side effects.
Researchers said EBV vaccines could also sharply reduce MS risk, though roughly 1,000 vaccinations would be needed to prevent one case and EBV's broader cancer links may shape that calculus.
If active EBV is the trigger, can new antivirals finally halt the progression of multiple sclerosis?
With EBV vaccine results due this month, could a shot soon prevent most new cases of multiple sclerosis?
Antivirals versus vaccines: Which new strategy targeting the 'mono virus' will win the race to conquer MS?
Landmark Study Confirms Epstein-Barr Virus as Direct Cause of Multiple Sclerosis: Mechanisms, Therapies, and Future Directions
Overview
Recent research has confirmed that the Epstein-Barr virus (EBV) is a direct cause of Multiple Sclerosis (MS), marking a major breakthrough in understanding the disease. Scientists discovered that during an EBV infection, specific immune cells called EBNA1 CD4+ T cells become activated and can mistakenly attack a brain protein known as anoctamin-2 (ANO2). This mistaken attack, known as molecular mimicry, leads to neuroinflammation, which is the damaging process behind MS. This new understanding explains how EBV triggers MS and opens the door for more targeted treatments and preventive strategies in the future.